- Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
- Arcus Biosciences Announces New Employment Inducement Grants
- Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
- Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
- Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
- Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
- Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
More ▼
Key statistics
On Friday, Arcus Biosciences Inc (RCUS:NYQ) closed at 15.81, 22.08% above the 52 week low of 12.95 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.33 |
---|---|
High | 15.91 |
Low | 15.08 |
Bid | 15.39 |
Offer | 16.95 |
Previous close | 14.98 |
Average volume | 468.29k |
---|---|
Shares outstanding | 90.95m |
Free float | 53.79m |
P/E (TTM) | -- |
Market cap | 1.44bn USD |
EPS (TTM) | -3.10 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 21:10 BST.
More ▼